These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 546864)

  • 21. The influence of age and multimorbidity on the pharmacokinetics and metabolism of spironolactone.
    Platt D; Abshagen U; Mühlberg W; Horn HJ; Schmitt-Rüth R; Vollmar J
    Arch Gerontol Geriatr; 1984 Jul; 3(2):147-59. PubMed ID: 6476975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone.
    Ho PC; Bourne DW; Triggs EJ; Heazlewood V
    Eur J Clin Pharmacol; 1984; 27(4):441-6. PubMed ID: 6519151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.
    DeFrance A; Armbruster D; Petty D; Cooper KC; Dasgupta A
    Ther Drug Monit; 2011 Feb; 33(1):128-31. PubMed ID: 21079546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of the serum concentration of spironolactone and its metabolites by high-performance liquid chromatography.
    Overdiek JW; Hermens WA; Merkus FW
    J Chromatogr; 1985 Jun; 341(2):279-85. PubMed ID: 4030980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous automated determination of spironolactone metabolites in serum.
    Neubert P; Koch K
    J Pharm Sci; 1977 Aug; 66(8):1131-4. PubMed ID: 894500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analytical issues in HPLC/MS/MS simultaneous assay of furosemide, spironolactone and canrenone in human plasma samples.
    Sora DI; Udrescu S; Albu F; David V; Medvedovici A
    J Pharm Biomed Anal; 2010 Sep; 52(5):734-40. PubMed ID: 20307949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Relative bioavailability in man of 2 pharmaceutical forms of canrenone].
    Bressolle F; Bres J; Faure A; Pistre MC
    Eur J Drug Metab Pharmacokinet; 1986; 11(3):165-70. PubMed ID: 3816872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.
    Dasgupta A; Johnson MJ
    J Clin Lab Anal; 2010; 24(6):413-7. PubMed ID: 21089173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of a simple fluorometric method on absorption of canrenone.
    Radó JP; Szende L; Takó J; Nagy O; Kozma C
    Int J Clin Pharmacol Biopharm; 1976 Mar; 13(2):123-6. PubMed ID: 1254376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incurred sample reanalysis: different evaluation approaches on data obtained for spironolactone and its active metabolite canrenone.
    Voicu V; Gheorghe MC; Sora ID; Sârbu C; Medvedovici A
    Bioanalysis; 2011 Jun; 3(12):1343-56. PubMed ID: 21679029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spironolactone metabolism in man studied by gas chromatography-mass spectrometry.
    Karim A; Hribar J; Aksamit W; Doherty M; Chinn LJ
    Drug Metab Dispos; 1975; 3(6):467-78. PubMed ID: 1221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples.
    Sandall JM; Millership JS; Collier PS; McElnay JC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jul; 839(1-2):36-44. PubMed ID: 16510319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spironolactone. II. Bioavailability.
    Karim A; Zagarella J; Hutsell TC; Chao A; Baltes BJ
    Clin Pharmacol Ther; 1976 Feb; 19(2):170-6. PubMed ID: 1261154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method.
    Dahlöf CG; Lundborg P; Persson BA; Regårdh CG
    Drug Metab Dispos; 1979; 7(2):103-7. PubMed ID: 38071
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of spironolactone and its main metabolite canrenone on the renin-angiotensin-aldosterone-system during long-term treatment in rats.
    Erbler HC
    Acta Endocrinol (Copenh); 1979 Jan; 90(1):147-56. PubMed ID: 760354
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.
    Dasgupta A; Johnson MJ; Sengupta TK
    J Clin Lab Anal; 2012 May; 26(3):143-7. PubMed ID: 22628228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids.
    Steimer W; Müller C; Eber B
    Clin Chem; 2002 Mar; 48(3):507-16. PubMed ID: 11861441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New insights into the pharmacokinetics of spironolactone.
    Overdiek HW; Hermens WA; Merkus FW
    Clin Pharmacol Ther; 1985 Oct; 38(4):469-74. PubMed ID: 4042530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Bioavailability studies of two spironolactone-preparations (author's transl)].
    Vergin H; Nuss U; Schwarzländer F; Strobel K; Weigand W; Hitzenberger G
    Arzneimittelforschung; 1981; 31(9):1498-503. PubMed ID: 7197963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats.
    Sadée W; Abshagen U; Finn C; Rietbrock N
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 283(3):303-18. PubMed ID: 4276758
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.